Epigenetic inactivation of the novel candidate tumor suppressor gene ITIH5 in colon cancer predicts unfavorable overall survival in the CpG island methylator phenotype

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69 - 90; http://dx.doi.org/10.3322/caac.20107; PMID: 21296855
   PubMed Web of Science ®Google Scholar
• Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 2011; 60:116 - 29; http://dx.doi.org/10.1136/gut.2009.206250; PMID: 20921207
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319:525 - 32; http://dx.doi.org/10.1056/NEJM198809013190901; PMID: 2841597
   PubMed Web of Science ®Google Scholar
• Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 2010; 7:153 - 62; http://dx.doi.org/10.1038/nrclinonc.2009.237; PMID: 20142816
   PubMed Web of Science ®Google Scholar
• Jass JR, Do KA, Simms LA, Iino H, Wynter C, Pillay SP, Searle J, Radford-Smith G, Young J, Leggett B. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 1998; 42:673 - 9; http://dx.doi.org/10.1136/gut.42.5.673; PMID: 9659163
   PubMed Web of Science ®Google Scholar
• Peel DJ, Ziogas A, Fox EA, Gildea M, Laham B, Clements E, Kolodner RD, Anton-Culver H. Characterization of hereditary nonpolyposis colorectal cancer families from a population-based series of cases. J Natl Cancer Inst 2000; 92:1517 - 22; http://dx.doi.org/10.1093/jnci/92.18.1517; PMID: 10995807
   PubMed Web of Science ®Google Scholar
• Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260:816 - 9; http://dx.doi.org/10.1126/science.8484122; PMID: 8484122
   PubMed Web of Science ®Google Scholar
• Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes’ B colorectal cancer patients: how much evidence is enough?. Ann Oncol 2003; 14:1026 - 38; http://dx.doi.org/10.1093/annonc/mdg284; PMID: 12853343
   PubMed Web of Science ®Google Scholar
• Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr., ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24:5313 - 27; http://dx.doi.org/10.1200/JCO.2006.08.2644; PMID: 17060676
   PubMed Web of Science ®Google Scholar
• Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138:2073 - 87, e3; http://dx.doi.org/10.1053/j.gastro.2009.12.064; PMID: 20420947
   PubMed Web of Science ®Google Scholar
• Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 2008; 29:673 - 80; http://dx.doi.org/10.1093/carcin/bgm228; PMID: 17942460
   PubMed Web of Science ®Google Scholar
• Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999; 96:8681 - 6; http://dx.doi.org/10.1073/pnas.96.15.8681; PMID: 10411935
   PubMed Web of Science ®Google Scholar
• Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38:787 - 93; http://dx.doi.org/10.1038/ng1834; PMID: 16804544
   PubMed Web of Science ®Google Scholar
• Ogino S, Odze RD, Kawasaki T, Brahmandam M, Kirkner GJ, Laird PW, Loda M, Fuchs CS. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol 2006; 30:1175 - 83; http://dx.doi.org/10.1097/01.pas.0000213266.84725.d0; PMID: 16931963
   PubMed Web of Science ®Google Scholar
• Toyota M, Ohe-Toyota M, Ahuja N, Issa JP. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A 2000; 97:710 - 5; http://dx.doi.org/10.1073/pnas.97.2.710; PMID: 10639144
   PubMed Web of Science ®Google Scholar
• van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B, van RM. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 2002; 51:797 - 802; http://dx.doi.org/10.1136/gut.51.6.797; PMID: 12427779
   PubMed Web of Science ®Google Scholar
• Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, O’Connor T, Ward R. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 2002; 122:1376 - 87; http://dx.doi.org/10.1053/gast.2002.32997; PMID: 11984524
   PubMed Web of Science ®Google Scholar
• Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B, van RM. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003; 9:2898 - 903; PMID: 12912934
   PubMed Web of Science ®Google Scholar
• Himmelfarb M, Klopocki E, Grube S, Staub E, Klaman I, Hinzmann B, Kristiansen G, Rosenthal A, Dürst M, Dahl E. ITIH5, a novel member of the inter-alpha-trypsin inhibitor heavy chain family is downregulated in breast cancer. Cancer Lett 2004; 204:69 - 77; http://dx.doi.org/10.1016/j.canlet.2003.09.011; PMID: 14744536
   PubMed Web of Science ®Google Scholar
• Hamm A, Veeck J, Bektas N, Wild PJ, Hartmann A, Heindrichs U, Kristiansen G, Werbowetski-Ogilvie T, Del Maestro R, Knuechel R, et al. Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysis. BMC Cancer 2008; 8:25; http://dx.doi.org/10.1186/1471-2407-8-25; PMID: 18226209
   PubMed Web of Science ®Google Scholar
• Veeck J, Chorovicer M, Naami A, Breuer E, Zafrakas M, Bektas N, Dürst M, Kristiansen G, Wild PJ, Hartmann A, et al. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation. Oncogene 2008; 27:865 - 76; http://dx.doi.org/10.1038/sj.onc.1210669; PMID: 17653090
   PubMed Web of Science ®Google Scholar
• Rose M, Gaisa NT, Antony P, Fiedler D, Heidenreich A, Otto W, Denzinger S, Bertz S, Hartmann A, Karl A, et al. Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours. Carcinogenesis 2014; 35:727 - 36; PMID: 24265292
   PubMed Web of Science ®Google Scholar
• Huang L, Yoneda M, Kimata K. A serum-derived hyaluronan-associated protein (SHAP) is the heavy chain of the inter alpha-trypsin inhibitor. J Biol Chem 1993; 268:26725 - 30; PMID: 7504674
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Gotoh J, Hirashima Y, Fujie M, Sugino D, Terao T. Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J Biol Chem 1995; 270:8361 - 6; http://dx.doi.org/10.1074/jbc.270.14.8361; PMID: 7713945
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Shinohara H, Fujie M, Gotoh J, Itoh M, Takeuchi K, Terao T. Inhibition of metastasis of Lewis lung carcinoma by urinary trypsin inhibitor in experimental and spontaneous metastasis models. Int J Cancer 1995; 63:455 - 62; http://dx.doi.org/10.1002/ijc.2910630326; PMID: 7591248
   PubMed Web of Science ®Google Scholar
• Veeck J, Breuer E, Rose M, Chorovicer M, Naami A, Bektas N, Alkaya S, von Serényi S, Horn F, Hartmann A, et al. [Novel prognostic marker in invasive breast cancer. ITIH5 expression is abrogated by aberrant promoter methylation]. Pathologe 2008; 29:Suppl 2 338 - 46; http://dx.doi.org/10.1007/s00292-008-1044-9; PMID: 18810445
   PubMedGoogle Scholar
• Kloten V, Becker B, Winner K, Schrauder MG, Fasching PA, Anzeneder T, Veeck J, Hartmann A, Knüchel R, Dahl E. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res 2013; 15:R4; http://dx.doi.org/10.1186/bcr3375; PMID: 23320751
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487:330 - 7; http://dx.doi.org/10.1038/nature11252; PMID: 22810696
   PubMed Web of Science ®Google Scholar
• Gröne J, Lenze D, Jurinovic V, Hummel M, Seidel H, Leder G, Beckmann G, Sommer A, Grützmann R, Pilarsky C, et al. Molecular profiles and clinical outcome of stage UICC II colon cancer patients. Int J Colorectal Dis 2011; 26:847 - 58; http://dx.doi.org/10.1007/s00384-011-1176-x; PMID: 21465190
   PubMed Web of Science ®Google Scholar
• Bae JM, Kim MJ, Kim JH, Koh JM, Cho NY, Kim TY, Kang GH. Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status. Virchows Arch 2011; 459:55 - 63; http://dx.doi.org/10.1007/s00428-011-1080-3; PMID: 21494758
   PubMed Web of Science ®Google Scholar
• Lee S, Cho NY, Yoo EJ, Kim JH, Kang GH. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch Pathol Lab Med 2008; 132:1657 - 65; PMID: 18834226
   PubMed Web of Science ®Google Scholar
• Iacopetta B. Are there two sides to colorectal cancer?. Int J Cancer 2002; 101:403 - 8; http://dx.doi.org/10.1002/ijc.10635; PMID: 12216066
   PubMed Web of Science ®Google Scholar
• Kapiteijn E, Liefers GJ, Los LC, Kranenbarg EK, Hermans J, Tollenaar RA, Moriya Y, van de Velde CJH, van Krieken JHJM. Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol 2001; 195:171 - 8; http://dx.doi.org/10.1002/path.918; PMID: 11592095
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646 - 74; http://dx.doi.org/10.1016/j.cell.2011.02.013; PMID: 21376230
   PubMed Web of Science ®Google Scholar
• Oing C, Jost E, Dahl E, Wilop S, Brümmendorf TH, Galm O. Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemia. Clin Epigenetics 2011; 2:419 - 23; http://dx.doi.org/10.1007/s13148-011-0043-5; PMID: 22704354
   PubMedGoogle Scholar
• Fleisher AS, Esteller M, Tamura G, Rashid A, Stine OC, Yin J, Zou TT, Abraham JM, Kong D, Nishizuka S, et al. Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene 2001; 20:329 - 35; http://dx.doi.org/10.1038/sj.onc.1204104; PMID: 11313962
   PubMed Web of Science ®Google Scholar
• Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4:988 - 93; http://dx.doi.org/10.1038/nrc1507; PMID: 15573120
   PubMed Web of Science ®Google Scholar
• Midgley R, Kerr D. Colorectal cancer. Lancet 1999; 353:391 - 9; http://dx.doi.org/10.1016/S0140-6736(98)07127-X; PMID: 9950460
   PubMed Web of Science ®Google Scholar
• Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist 2010; 15:699 - 731; http://dx.doi.org/10.1634/theoncologist.2010-0025; PMID: 20584808
   PubMed Web of Science ®Google Scholar
• Kornmann M, Formentini A, Ette C, Henne-Bruns D, Kron M, Sander S, Baumann W, Kreuser ED, Staib L, Link KH. Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. Eur J Surg Oncol 2008; 34:1316 - 21; http://dx.doi.org/10.1016/j.ejso.2008.01.019; PMID: 18313881
   PubMed Web of Science ®Google Scholar
• Benson AB 3rd. New approaches to the adjuvant therapy of colon cancer. Oncologist 2006; 11:973 - 80; http://dx.doi.org/10.1634/theoncologist.11-9-973; PMID: 17030637
   PubMed Web of Science ®Google Scholar
• Fink L, Seeger W, Ermert L, Hänze J, Stahl U, Grimminger F, Kummer W, Bohle RM. Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med 1998; 4:1329 - 33; http://dx.doi.org/10.1038/3327; PMID: 9809560
   PubMed Web of Science ®Google Scholar
• Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, Galm O, Camara O, Dürst M, Kristiansen G, et al. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene 2006; 25:3479 - 88; http://dx.doi.org/10.1038/sj.onc.1209386; PMID: 16449975
   PubMed Web of Science ®Google Scholar
• Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39:561 - 77; PMID: 8472349
   PubMed Web of Science ®Google Scholar